Skip to main content
SpringerLink
Log in

Effect of a long-acting somatostatin analogue (octreotide) on circulating tachykinins and the pentagastrin-induced carcinoid flush

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

Cutaneous flushing was provoked in seven patients with metastatic carcinoid tumours and the carcinoid syndrome by an intravenous injection of pentagastrin (0.6 µg·kg−1 body weight). The patients were studied before and 1 h after a subcutaneous injection of the long-acting somatostatin analogue octreotide 50 µg (Sandostatin). The severity of the carcinoid flush in all the patients was reduced by administration of the analogue. The rise in facial temperature was 1.3 (0.3)° C before and 0.8 (0.2)° C after octreotide.

Six patients responded to pentagastrin with a rise in the circulating neurokinin A-like immunoreactivity (NKA-LI) and five patients with a rise in circulating substance P-like immunoreactivity (SP-LI). No cutaneous flushing or rise in tachykinin concentration was observed in healthy subjects (n=6) after injection of pentagastrin. The rise in NKA-LI in the patients was decreased by 61 (14)% and the rise in SP-LI by 54 (13)% after octreotide. Although flushing still occurred, the tachykinin response in two patients was completely abolished.

The data demonstrate that the release of tachykinins from carcinoid tumours during pentagastrin-induced flushing is subject to partial inhibition by octreotide. However, the occurrence of a flush in some patients in the absence of a detectable rise in circulating tachykinins indicates that the latter peptides cannot be the sole causative agent of the carcinoid flush.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Creutzfeldt W, Stöckmann F (1987) Carcinoids and carcinoid syndrome. Am J Med 82 [Suppl 5B]: 4–16

    Article  PubMed  CAS  Google Scholar 

  2. Frölich JC, Bloomgarden ZT, Oates JA, McGuigan JE, Rabinowitwz D (1978) The carcinoid flush. Provocation by pentagastrin and inhibition by somatostatin. N Engl J Med 299: 1055–1957

    Article  PubMed  Google Scholar 

  3. Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Marbach P, Petcher TJ, Pless J (1982) SMS 201-995: A very potent and selective octapeptide analogue of somatostatin with prolonge action. Life Sci 31: 1133–1141

    Article  PubMed  CAS  Google Scholar 

  4. Kraenzlin ME, Ch'ng JC, Wood SM, Bloom SR (1983) Can inhibition of hormone secretion be associated with endocrine tumour shrinkage. Lancet 2: 1501

    Article  PubMed  CAS  Google Scholar 

  5. Maton PN, O'Dorisio TM, Howe BA, McArthur KE, Howard JM, Cherner JA, Malarkey TB, Collen MJ, Gardner JD, Jensen RT (1985) Effect of a long-acting somatostatin analogue (SMS 201-995) in a patient with pancreatic cholera. N Engl J Med 312: 17–21

    Article  PubMed  CAS  Google Scholar 

  6. Buchanan KD, Shaw C, O'Hare MMT, Dalzell G (1986) Evaluation of SMS 201-995 in gastrointestinal APUDomas. Scand J Gastroenterol 21 [Suppl 119]: 199–205

    Google Scholar 

  7. Wood SM, Kraenzlin ME, Adrian TE, Bloom SR (1985) Treatment of patients with pancreatic endocrine tumours using a new long-acting somatostatin analogue: Symptomatic and peptide responses. Gut 26: 438–444

    PubMed  CAS  Google Scholar 

  8. Stöckmann F, Richter G, Lembcke B, Conlon JM, Creutzfeldt W (1986) Long-term treatment of patients with endocrine gastrointestinal tumours with the somatostatin analogue SMS 201-995. Scand J Gastroenterol 21 [Suppl 119]: 230–237

    Google Scholar 

  9. Schrezenmeir J, Plewe G, Stürmer W, Kahaly G, Oppermann D, Krause U, Del Pozo E, Kasper H, Beyer J (1986) Treatment of APUDomas with the long-acting somatostatin analogue SMS 201-995. Investigations of therapeutic use and digestive side-effects. Scand J Gastroenterol 21 [Suppl 119]: 223–227

    Google Scholar 

  10. Comi RJ, Gesundheit N, Murry L, Gordon P, Weintraub RD (1987) Response of thyrotropin-secreting pituitary adenomas to a long-acting somatostatin analogue. N Engl J Med 317: 12–17

    Article  PubMed  CAS  Google Scholar 

  11. Von Werder K, Losa M, Müller OA, Schweiberer L, Fahlbusch R, Del Pozo E (1984) Treatment of metastasising GRF-producing tumour with a long-acting somatostatin analogue. Lancet 2: 282–283

    Article  Google Scholar 

  12. Kvols LK, Moertel CG, O'Connell MJ, Shutt AJ, Rubin J, Hahn RG (1986) Treatment of the malignant carcinoid syndrome. N Engl J Med 315: 663–666

    Article  PubMed  CAS  Google Scholar 

  13. Richter G, Stöckmann F, Lembcke B, Conlon JM, Creutzfeldt W (1986) Short-term administration of the somatostatin analogue SMS 201-995 in patients with carcinoid tumours. Scand J Gastroenterol 21 [Suppl 119]: 193–198

    Google Scholar 

  14. Emson PC, Gilbert RFT, Martensson H, Nobin A (1984) Elevated concentrations of substance P and 5-HT in plasma in patients with carcinoid tumors. Cancer 54: 715–718

    Article  PubMed  CAS  Google Scholar 

  15. Norheim I, Theodorsson-Norheim E, Brodin E, Öberg K (1986) Tachykinins in carcinoid tumors. Their use as tumor marker and possible role in the carcinoid flush. J Clin Endocrinol Metab 63: 605–612

    Article  PubMed  CAS  Google Scholar 

  16. Conlon JM, Deacon CF, Richter G, Stöckmann F, Creutzfeldt W (1987) Circulating tachykinins (substance P, neurokinin A, neuropeptide K) and the carcinoid flush. Scand J Gastroenterol 22: 97–105

    PubMed  CAS  Google Scholar 

  17. Falkmer S, Martensson H, Nobin A, Sundler F (1984) Peptide hormones in various types of gastro-entero-pancreatic tumors: immunohistochemical patterns and evolutionary background. Prog Cancer Res Ther 31: 597–610

    Google Scholar 

  18. Del Pozo E, Neufeld M, Schlüter K, Tortosa F, Clarenbach P, Bieder E, Wendel L, Nüesch E, Marbach P, Cramer H, Kerp L (1986) Endocrine profile of a long-acting somatostatin derivative SMS 201-995. Study in normal volunteers following subcutaneous administration. Acta Endocrinol 111: 433–439

    PubMed  Google Scholar 

  19. Conlon JM, Sheehan L (1983) Conversion of substance P to C-terminal fragments in human plasma. Regul Pept 7: 335–345

    Article  PubMed  CAS  Google Scholar 

  20. Deacon CF, Conlon JM (1987) Biosynthesis of tachykinins (substance P, neurokinin A and neuropeptide K) in neurons of the guinea pig myenteric plexus. Neurochem Int 10: 559–564

    Article  CAS  PubMed  Google Scholar 

  21. Conlon JM, Deacon CF, Richter G, Schmidt WE, Stöckmann F, Creutzfeld W (1986) Measurement and partial characterization of the multiple forms of neurokinin A-like immunoreactivity in carcinoid tumours. Regul Pept 13: 183–186

    Article  PubMed  CAS  Google Scholar 

  22. Kraenzlin ME, Wood SM, Neufeld M, Adrian TE, Bloom SR (1985) Effect of long acting somatostatin-analogue SMS 201-995 on gut hormone secretion in normal subjects. Experientia 41: 739–740

    Article  Google Scholar 

  23. Martling C-R, Theodorsson-Norheim E, Norheim I, Lundberg JM (1987) Bronchoconstrictor and hypotensive effects in relation to pharmacokinetics of tachykinins in the guinea pig — evidence for extraneuronal cleavage of neuropeptide K to neurokinin A. Naunyn Schmidebergs Arch Pharmacol 33: 183–189

    Article  Google Scholar 

  24. Schaffalitzky de Muckadell OB, Aggestrup S, Stentoft P (1986) Flushing and plasma substance P concentrations during infusions of synthetic substance P in normal man. Scand J Gastroenterol 21: 498–502

    PubMed  CAS  Google Scholar 

  25. Balks HJ, Conlon JM, Creutzfeldt W, Stöckmann F (1988) Circulating bradykinin-like immunoreactivity and the pentagastrin-induced carcinoid flush. Clin Endocrinol 28: 141–151

    Google Scholar 

  26. Oates JA, Melmon K, Sjoerdsma A, Gillespie L, Mason DT (1964) Release of a kinin peptide in the carcinoid syndrome. Lancet 2: 514–517

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Research Group for Gastrointestinal Endocrinology, Max-Planck-Gesellschaft, Federal Republic of Germany

    H. J. Balks, J. M. Conlon, W. Creutzfeldt & F. Stöckmann

  2. Department of Medicine, University of Göttingen, Göttingen, Federal Republic of Germany

    H. J. Balks, J. M. Conlon, W. Creutzfeldt & F. Stöckmann

  3. Department of Biochemistry The Medical School, Creighton University, 68178, Omaha, Nebraska, USA

    J. M. Conlon

Authors
  1. H. J. Balks
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. M. Conlon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W. Creutzfeldt
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F. Stöckmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Balks, H.J., Conlon, J.M., Creutzfeldt, W. et al. Effect of a long-acting somatostatin analogue (octreotide) on circulating tachykinins and the pentagastrin-induced carcinoid flush. Eur J Clin Pharmacol 36, 133–137 (1989). https://doi.org/10.1007/BF00609184

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00609184

Key words

Search

Navigation